文献速递淋巴瘤

剂量调整EPOCH联合利妥昔单抗治疗的淋巴瘤患者中枢神经系统复发的频率、危险因素与结局

Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
PubMed 文献 · Am J Hematol · 2017-08-17

本文回顾性分析223例接受EPOCH-R一线治疗的非霍奇金淋巴瘤患者(72%为DLBCL),5.8%出现中枢神经系统复发,38.6%接受了CNS预防。接受与未接受CNS预防者的CNS复发率、OS及PFS均无差异。诊断时乳酸脱氢酶大于正常上限两倍及结外病变者CNS复发风险显著更高(P=.0247和0.022)。

要点

  • EPOCH-R一线治疗NHL患者CNS复发率5.8%,与R-CHOP报告接近。
  • 接受与未接受CNS预防者CNS复发率、OS、PFS均无差异。
  • LDH>2倍正常上限及结外病变者CNS复发风险显著更高。

核心结论

  • 该人群CNS复发率接近6%,与接受R-CHOP者的报告无显著差异。
  • 结果提示CNS预防或可在具有特定高危特征的EPOCH-R治疗患者中更有选择性地使用。

研究设计与样本

  • 对接受EPOCH-R一线治疗的NHL患者进行病历回顾性分析,共纳入223例符合标准者,72%为DLBCL。
  • 收集基线与治疗特征(包括是否接受CNS定向治疗),评估OS、PFS及进展至CNS受累情况。

主要发现

  • 全部患者中5.8%发生CNS复发,38.6%接受了CNS预防。
  • 接受与未接受CNS预防者之间CNS复发率、OS及PFS均无差异。
  • 诊断时血清乳酸脱氢酶大于正常上限两倍者及有结外病变者CNS复发显著更多(P=.0247和0.022)。

临床怎么用

  • 作者认为,CNS预防或可在接受EPOCH-R治疗且具有特定高危特征的患者中更有选择性地使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) is a rare but serious complication that carries a poor prognosis. The use of infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) for frontline treatment of diffuse large B cell lymphoma (DLBCL) is increasing, though little is known about incidence of and risk factors for CNS relapse with this regimen PATIENTS AND METHODS: We completed a chart review of patients with NHL who received EPOCH-R as front line therapy. Data obtained included baseline and treatment characteristics including if patients received CNS directed therapy. We measured overall survival (OS), progression free survival (PFS), and progression to CNS involvement. RESULTS: We identified 223 patients who met the inclusion criteria, 72% had DLBCL. Of all the patients, 5.8% experienced CNS relapse, and 38.6% were treated with CNS prophylaxis. There was no difference in rate of CNS relapse, OS, or PFS between patients who had and had not received CNS prophylaxis. Patients whose serum lactate dehydrogenase was greater than twice the upper limit of normal at diagnosis and those with extranodal disease were significantly more likely to have CNS relapse (P = .0247 and 0.022, respectively) than their counterparts. CONCLUSIONS: The rate of CNS relapse in this patient population approaches 6%, not significantly different from reports on those receiving R-CHOP. The results of this study suggest that CNS prophylaxis might be more selectively used among patients treated with EPOCH-R with certain high-risk features.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Malecek MK, Petrich AM, Rozell S, et al. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. Am J Hematol. 2017. PMID: 28719025. doi:10.1002/ajh.24864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。